Oncology Medical News about Pamidronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-Term Effects of Pamidronate in Thalassemic Patients with Severe Bone Mineral Density Deficits
Hemoglobin, 10/23/09

Leung TF et al. – Osteoporosis is a common complication in thalassemia major (TM). Our previous study demonstrated severe bone mineral density (BMD) deficits at spine and hip in 62 and 35% of TM patients. This study assessed the effects of different treatments (calcium, vitamin D and bisphosphonate) on patients' BMD, which was measured at baseline and after 3–year treatments by dual energy X–ray absorptiometry (DEXA). Long–term improvement in BMD in TM patients was observed with bisphosphonate but not calcium and vitamin D treatment.

<< Previous
Recovery of paraneoplastic hypercalcemia by sunitinib treatment...

Next >>
A New Era in Iron Chelation Therapy: The Design of Optimal,...

Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw
Journal of Clinical Oncology, 10/12/09 Relevance Score: 77%